Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J E Crowe

Showing results (51-60 of 70) with videos related to

Pageof 7
Sort By:
The Journal of Infectious Diseases|April 1, 1996
Live subgroup B respiratory syncytial virus vaccines that are attenuated, genetically stable, and immunogenic in rodents and nonhuman primatesJ E Crowe, P T Bui, C Y Firestone, et al.
The Journal of Infectious Diseases|April 16, 1998
Isolation of a second recombinant human respiratory syncytial virus monoclonal antibody fragment (Fab RSVF2-5) that exhibits therapeutic efficacy in vivoJ E Crowe, P S Gilmour, B R Murphy, et al.
Ultramicroscopy|May 30, 2006
Automated image analysis of atomic force microscopy images of rotavirus particlesS Venkataraman, D P Allison, H Qi, et al.
Clinical and Diagnostic Laboratory Immunology|November 1, 1994
Isolation and characterization of a chimpanzee monoclonal antibody to the G glycoprotein of human respiratory syncytial virusJ E Crowe, P Y Cheung, E F Wallace, et al.
Journal of Virology|February 1, 1995
Cytotoxic T cells specific for a single peptide on the M2 protein of respiratory syncytial virus are the sole mediators of resistance induced by immunization with M2 encoded by a recombinant vaccinia virusA B Kulkarni, P L Collins, I Bacik, et al.
Vaccine|April 1, 1995
Isolation and characterization of a highly attenuated respiratory syncytial virus (RSV) vaccine candidate by mutagenesis of the incompletely attenuated RSV A2 ts-1 NG-1 mutant virusK H Hsu, J E Crowe, M D Lubeck, et al.
Journal of Virology|January 9, 1999
Addition of a missense mutation present in the L gene of respiratory syncytial virus (RSV) cpts530/1030 to RSV vaccine candidate cpts248/404 increases its attenuation and temperature sensitivityS S Whitehead, C Y Firestone, R A Karron, et al.
Vaccine|June 1, 1994
Satisfactorily attenuated and protective mutants derived from a partially attenuated cold-passaged respiratory syncytial virus mutant by introduction of additional attenuating mutations during chemical mutagenesisJ E Crowe, P T Bui, W T London, et al.
The Journal of Infectious Diseases|December 12, 1997
Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and childrenR A Karron, P F Wright, J E Crowe, et al.
Journal of Virology|March 12, 1999
Human antibody responses to mature and immature forms of viral envelope in respiratory syncytial virus infection: significance for subunit vaccinesH Sakurai, R A Williamson, J E Crowe, et al.
Pageof 7

Showing results (51-60 of 70) with videos related to

Sort By:
Pageof 7
The Journal of Infectious Diseases|April 1, 1996
Live subgroup B respiratory syncytial virus vaccines that are attenuated, genetically stable, and immunogenic in rodents and nonhuman primatesJ E Crowe, P T Bui, C Y Firestone, et al.
The Journal of Infectious Diseases|April 16, 1998
Isolation of a second recombinant human respiratory syncytial virus monoclonal antibody fragment (Fab RSVF2-5) that exhibits therapeutic efficacy in vivoJ E Crowe, P S Gilmour, B R Murphy, et al.
Ultramicroscopy|May 30, 2006
Automated image analysis of atomic force microscopy images of rotavirus particlesS Venkataraman, D P Allison, H Qi, et al.
Clinical and Diagnostic Laboratory Immunology|November 1, 1994
Isolation and characterization of a chimpanzee monoclonal antibody to the G glycoprotein of human respiratory syncytial virusJ E Crowe, P Y Cheung, E F Wallace, et al.
Journal of Virology|February 1, 1995
Cytotoxic T cells specific for a single peptide on the M2 protein of respiratory syncytial virus are the sole mediators of resistance induced by immunization with M2 encoded by a recombinant vaccinia virusA B Kulkarni, P L Collins, I Bacik, et al.
Vaccine|April 1, 1995
Isolation and characterization of a highly attenuated respiratory syncytial virus (RSV) vaccine candidate by mutagenesis of the incompletely attenuated RSV A2 ts-1 NG-1 mutant virusK H Hsu, J E Crowe, M D Lubeck, et al.
Journal of Virology|January 9, 1999
Addition of a missense mutation present in the L gene of respiratory syncytial virus (RSV) cpts530/1030 to RSV vaccine candidate cpts248/404 increases its attenuation and temperature sensitivityS S Whitehead, C Y Firestone, R A Karron, et al.
Vaccine|June 1, 1994
Satisfactorily attenuated and protective mutants derived from a partially attenuated cold-passaged respiratory syncytial virus mutant by introduction of additional attenuating mutations during chemical mutagenesisJ E Crowe, P T Bui, W T London, et al.
The Journal of Infectious Diseases|December 12, 1997
Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and childrenR A Karron, P F Wright, J E Crowe, et al.
Journal of Virology|March 12, 1999
Human antibody responses to mature and immature forms of viral envelope in respiratory syncytial virus infection: significance for subunit vaccinesH Sakurai, R A Williamson, J E Crowe, et al.
Pageof 7